Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for a crucial patent covering its leading tumor-targeted vaccine technology for cancer immunotherapy. The issuance of this valuable patent protection for tumor targeted immunotherapy follows on the heels of two international patents covering targeted gene medicine in the U.S. and Europe, respectively, and places Epeius Biotech at the forefront of these emerging fields of clinical medicine with best-of-breed solutions and incontrovertible proofs-of-principle in the clinic.